Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Vitamin K2 and Improved Vitamin K Status

Doses used in studies

mcg/week: 2,000 (median 2,000, IQR 2,000–2,000) — 1 study

Time to effect

Median: 18 months · IQR 18 months–18 months · Range 18 months–18 months — Reported in 1 of 1 study

1 of 1 paper

Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.
- 2019-11-08
- RCT · n = 132
- Journal of the American Society of Nephrology : JASN 31(1)
- - An S De Vriese
  - Rogier Caluwé
  - Lotte Pyfferoen
  - Dirk De Bacquer
  - Koen De Boeck
  - Joost Delanote
  - Didier De Surgeloose
  - Piet Van Hoenacker
  - Bruno Van Vlem
  - Francis Verbeke
- PubMed: 31704740
- DOI: 10.1681/asn.2019060579
2 Insights on
- Improved Vitamin K Status
- High evidence
- Large Human Trial
- Highly Cited
- Clinical
whereas levels decreased in the rivaroxaban group and to a larger extent in the rivaroxaban+vitamin K2 group
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Dose
2000 µg thrice weekly